BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

  April 16, 2026

   · 

  7 min read
• Press Releases

  Microbix Presenting at the 2026 Bloom Burton Conference

  April 16, 2026

   · 

  4 min read
• Press Releases

  Araceli Biosciences Appoints Christine Tsingos to Board of Directors

  April 16, 2026

   · 

  2 min read
• Press Releases

  ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

  April 16, 2026

   · 

  4 min read
• Press Releases

  ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

  April 16, 2026

   · 

  15 min read
• Press Releases

  BioMed X and Servier Launch First Research Team in France to Pioneer AI-Driven Antibody Engineering

  · New XSeed Labs team at Servier’s Paris-Saclay campus brings together AI and immunology expertise to advance next-generation biologics.

  April 16, 2026

   · 

  1 min read
• 

  Artificial intelligence

  Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma

  In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big Pharma companies such as Sanofi, Novo Nordisk and AbbVie.

  April 16, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Funding

  Revolution doubles stock offering target to $2B following pancreatic cancer win

  After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt offering.

  April 16, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

  April 16, 2026

   · 

  7 min read
• Press Releases

  Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

  April 16, 2026

   · 

  6 min read